Get Your Hands on the World's First $1 Billion Cannabis Drug

When it comes to biotech, Wall Street tends to overreact. Though there's no reason for it to be there, biotech is in the dog house, and investors have been conditioned to punish the sector and its stocks whenever the opportunity presents itself.

You see, there are three main reasons biotech is down: Wall Street is worried about high and rising drug prices, the impact of a possible trade war on foreign sales, and expiring patents for some older medications.

Over the last several years, for example, I've read a number of Wall Street reports about the so-called "biotech patent cliff." Simply stated, a drug falls off that "cliff" when its patent runs out and it starts facing competition from generics.

And a number of successful drugs out there are rapidly approaching their patent cliffs.

That sounds bad.

But there are good things happening in biotech, as well. In fact, what you don't hear much about is that the industry is about to bust out.

For example, I was thrilled to see a recent report from Clarivant Analytics, a research firm that works closely with industry leaders and top universities, which says a total of 12 compounds being released in 2018 could become blockbusters.

So I went through the data and found one ultimate biotech blockbuster that I think could lead the pack.